Our results suggest that efforts to reduce racial disparities in underdiagnosis are warranted. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
32,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our results suggest that efforts to reduce racial disparities in underdiagnosis are warranted. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment, including dementia, is a common but poorly recognized problem among patients with end-stage renal disease (ESRD), affecting 16-38% of patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
China accounts for 1/5 of the global population and China faces a particularly heavy dementia burden due to its rapidly ageing population. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this article, the challenges faced by several noted population studies for Alzheimer dementia in operationalizing current clinical diagnostic criteria for Alzheimer's disease (AD) have been reviewed. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A 7-min window, corresponding to minutes 1-8 (frames 5-15), produced the highest voxelwise correlation between (18)F-FDG and pPIB (R = 0.78 ± 0.05). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Data on 1888 patients seen at Alzheimer's Disease Diagnostic and Treatment Centers in California were used to examine possible differences in Mini-Mental State Examination (MMSE) results for different racial-ethnic groups. 2 key findings →
Participants: 1,888 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The ToAI framework followed a nine-step process: preparation, translation, native-speaker review, VIP team review, external panel review, pilot testing, proofreading, final formatting, and ongoing review and improvement. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising biomarker of astrocytic reactivity in preclinical Alzheimer´s Disease (AD). 4 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of abnormal neurodegeneration amidst normal cognitive aging is crucial. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Twenty-six percent of eligible ED users contacted elected for study enrollment. 5 key findings →
Participants: 160 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundClinician communication at the time of a dementia diagnosis often inadequately addresses patient and caregiver needs. 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory Questionnaire (NPI-Q), and Clinical Dementia Rating (CDR) scale plus National Alzheimer's Coordinating Center-Frontotemporal Lobar Degeneration module (NACC-FTLD). 5 key findings →
Participants: 168 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous syndrome, characterized by progressive decline in behaviour or language associated with degeneration of the frontal and anterior temporal lobes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As the U.S. population ages, Alzheimer's disease and related dementias (ADRD) cases are increasing, resulting in long wait times for specialist care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Health disparities in dementia care are amplified among aging multilingual communities relative to their monolingual English-speaking counterparts, as social determinants of health and significant gaps in culturally responsive practice can contribute to misdiagnosis, underdiagnosis, and delays in intervention. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Impairment in the comprehension of morphosyntactic and transitivity information does not feature in current diagnostic guidelines for primary progressive aphasia (PPA) or Alzheimers Diseases (AD), despite research reporting delayed sensitivity or insensitivity of these clinical populations to these linguistic domains. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Service members with traumatic brain injury are at approximately two- to four-fold higher risk of Alzheimers disease or related dementias than those without such an injury, with risk increasing with injury severity. 5 key findings →
Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For TabCAT tests, there were no notable floor or ceiling effects, and test scores were associated with age and education as expected. 3 key findings →
Design: cohort study Participants: 563 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,580 records, built mostly from automated pulls of Europe PMC (66.9% of the library) and OpenAlex (15.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated